CELL INTELLIGENCE · 肿瘤细胞治疗研究

整合 CD28、4-1BB 和 CD27 的三重共刺激 GD2-CAR-T 细胞在实体瘤模型中介导强效细胞毒性并减少耗竭

Triple-costimulatory GD2-CAR T cells incorporating CD28, 4-1BB and CD27 mediate potent cytotoxicity and reduce exhaustion in solid tumour models.

精准医学在神经母细胞瘤中的作用：靶向治疗与个体化方法——叙述性综述

The Role of Precision Medicine in Neuroblastoma: Targeted Therapies and Personalized Approaches-A Narrative Review.

精准医学通过提高诊断特异性和治疗效果并降低毒性，改变了神经母细胞瘤的治疗。在新兴策略中，ALK 靶向治疗和抗 GD2 免疫治疗显示出强大的临床潜力，尽管仍需进一步验证以改善患病儿童的生存率和生活质量。

CAR-T 细胞疗法治疗黑色素瘤：I 期临床试验系统综述

Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Melanoma: A Systematic Review of Phase One Clinical Trials.

优化儿童肿瘤学中的疗效-毒性范式：免疫治疗与生存结局的叙述性综述

Optimizing the Efficacy-Toxicity Paradigm in Pediatric Oncology: A Narrative Review of Immunotherapy and Survivorship Outcomes.

免疫治疗改变了结局，但时机至关重要，因为更早应用可显著改善生存。

玻璃体腔内注射 GD2 特异性 CAR-T 细胞治疗难治性视网膜母细胞瘤

Intravitreal GD2-Specific Chimeric Antigen Receptor T-Cell Therapy for Refractory Retinoblastoma.

B7-H3 和 GD2 过表达作为视网膜母细胞瘤的免疫治疗靶点

B7-H3 and GD2 overexpression as immunotherapeutic targets in retinoblastoma.

新希望：儿童弥漫性中线胶质瘤靶向治疗的临床进展

A new hope: Clinical advances in targeted therapies for pediatric diffuse midline glioma.

神经节苷脂治疗在癌症中的分子见解与治疗机会

Ganglioside therapy in cancer molecular insights and therapeutic opportunities.

使用锆-89 标记的 APOMAB®检测体内免疫介导的肿瘤细胞死亡

Detection of immune-mediated tumour cell death in vivo using Zirconium-89-labeled APOMAB®.

将 CD3/GD2 双特异性 T 细胞衔接器与人 Vγ9Vδ2 T 细胞联合可在体外促进神经母细胞瘤细胞的靶向和杀伤

Combining CD3/GD2 bispecific T cell engager with human Vγ9Vδ2 T cells facilitates neuroblastoma cell targeting and killing in vitro.